A groundbreaking malaria treatment for newborns and young infants is expected to be approved in several African countries soon. The drug, known as Coartem Baby, has already received approval in Ghana and is anticipated to gain approval in eight more countries, including Kenya, Nigeria, and Uganda, within the next 90 days. This marks a significant step in addressing malaria, a disease that poses a severe risk to young children.
Coartem Baby is specifically formulated for babies weighing between 2 and 5 kilograms. Previously, the smallest patients were treated with medications designed for older children, which could lead to dangerous overdoses. Novartis, the drug’s manufacturer, emphasizes that this new treatment is crucial for ensuring that even the most vulnerable infants receive the care they need.
The World Health Organization reported that malaria caused 263 million cases and 597,000 deaths in 2023, predominantly affecting children under five in Africa. Novartis plans to distribute Coartem Baby on a not-for-profit basis, aiming to make this essential medicine widely available, as health leaders stress the importance of tackling malaria to save young lives.

